Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic landscape and future direction of metastatic colorectal cancer
H Bando, A Ohtsu, T Yoshino - Nature Reviews Gastroenterology & …, 2023 - nature.com
In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …
Precision oncology in metastatic colorectal cancer—from biology to medicine
Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …
therapies for patients with multiple cancer types, including melanoma, breast and lung …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre …
Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2 …
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2 …
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …
cancer, although there are currently no approved HER2-targeted therapies for colorectal …
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …
New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
[PDF][PDF] HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target
S Ahcene Djaballah, F Daniel, A Milani… - American Society of …, 2022 - researchgate.net
Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …
Update on targeted therapy and immunotherapy for metastatic colorectal cancer
Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of
cancer-related death. The mainstay of treatment for metastatic colorectal cancer is …
cancer-related death. The mainstay of treatment for metastatic colorectal cancer is …
Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: a review
Importance Amplification ofERBB2 (formerly referred to asHER2) is present in nearly 3% of
patients with metastatic colorectal cancer overall and 5% of patients …
patients with metastatic colorectal cancer overall and 5% of patients …
HER2 targeted therapy in colorectal cancer: New horizons
Despite recent advances in the treatment of metastatic colorectal cancer (mCRC), 5 years
survival rates remain low. Chemotherapy remains as the mainstay of treatment with only few …
survival rates remain low. Chemotherapy remains as the mainstay of treatment with only few …